Oncosil Medical Ltd Positions TRIPP FFX Study for ESMO GI 2026 Presentation
OncoSil’s TRIPP-FFX pancreatic cancer study abstract published ahead of ESMO GI 2026 presentation
OncoSil Medical (ASX: OSL) has had the abstract for its TRIPP-FFX study published on the European Society for Medical Oncology Gastrointestinal Cancers Congress (ESMO GI 2026) website, ahead of a scheduled presentation on 4 July 2026.
OncoSil Medical is a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC). The abstract has been selected for a Rapid Oral Presentation.
The study data was previously referenced in the Company’s announcements on 9 June and 10 June 2026.
When big ASX news breaks, our subscribers know first
Presentation details and study conclusion
The full abstract is titled “TRIPP-FFX: An open-label, multi-centre, randomized study of TaRgeted Intratumoural placement of phosphorous-32 microparticles added to FOLFIRINOX (FFX) versus FFX alone in patients with unresectable locally advanced pancreatic cancer (uLAPC).”
Presentation details are as follows:
-
Presentation Type: Rapid Oral Presentation
-
Date: 4 July 2026
-
Time: 8:30am CEST (4:30pm AEST)
-
Presenter: Professor Michele Milella, University of Verona, Italy
The study investigators summarised their findings in the abstract conclusion.
Study Investigators’ Conclusion
“This non-comparative study met the primary endpoints, with limited and manageable toxicities and encouraging LDCR and survival endpoints following the addition of P-32 microparticles to FFX.”
The study meeting its primary endpoints is the central takeaway for investors. No new numerical endpoint figures were disclosed in this announcement, with results described qualitatively as showing “manageable toxicities” and “encouraging” survival outcomes.
The TRIPP-FFX primary endpoints included both safety/tolerability and a local disease control rate threshold, with the trial recording an 82.2% local disease control rate at 16 weeks and a median overall survival of 18.3 months in the OncoSil plus FOLFIRINOX arm.
Understanding the OncoSil device and why pancreatic cancer matters
The OncoSil™ device works through the selected and targeted intratumoural placement of Phosphorous-32 (³²P) Microparticles alongside chemotherapy. In simple terms, this means radioactive particles are placed directly inside the tumour rather than delivered from outside the body.
According to the Company, this targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs.
The clinical need is substantial. Pancreatic cancer is the 12th most common cancer in men and the 11th most common in women globally, with approximately 500,000 new cases detected every year. Because it is generally diagnosed at a later stage, the disease carries a poor prognosis for long-term survival.
A large, underserved patient population with poor outcomes underpins the commercial opportunity for a differentiated localised treatment.
Regulatory footprint and the investment case
OncoSil Medical already holds an established regulatory and commercial footprint, which provides context for why supportive clinical data matters to the broader thesis.
| Status Item | Detail |
|---|---|
| CE Marking | Marketing authorisation in the EU and UK |
| Breakthrough Device designation | Europe and the United States |
| Approved for sale | 30+ countries (including EU, UK, Australia, Türkiye, Israel) |
| Commercial treatments undertaken | Spain, Italy, Austria, Germany, Greece, Türkiye, Portugal, Israel, UK |
With commercial infrastructure already in place across more than 30 markets, supportive clinical evidence for the FOLFIRINOX combination is backed by an established regulatory and commercial presence across already-approved markets.
The next major ASX story will hit our subscribers first
What’s next for OncoSil
The near-term catalyst for investors is the Rapid Oral Presentation scheduled for 4 July 2026, where the initial results will be presented by Professor Michele Milella at the ESMO GI 2026 Congress.
This presentation is the next milestone where the market gains visibility on the initial results from the TRIPP-FFX study.
Alongside the ESMO GI presentation, OncoSil’s FDA Humanitarian Device Exemption application reached its final administrative stage in June 2026, with the agency having resolved all substantive review questions and a decision targeted within 75 days, making potential US market entry another near-term catalyst running in parallel.
Don’t Miss the Next Healthcare Breakthrough on the ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done. Join 20,000+ subscribers staying ahead of market-moving announcements the moment they drop. Click the “Free Alerts” button at Big News Blast to make sure you never miss the next major healthcare catalyst.